The architecture powering Zero Trust at the edge

Tern plc

The shift to Zero Trust security has placed a new spotlight on the most fundamental yet overlooked layer of the digital ecosystem: device identity. For enterprises managing vast fleets of connected assets, the moment of onboarding is no longer a technical footnote, it is the critical juncture where long-term trust, compliance, and resilience begin.

What has long been treated as an administrative step in the supply chain has now become a strategic control point. Weak or reused device identities have been the unseen entry point for some of the most serious operational breaches, from energy grid outages to compromised medical systems. Yet, the tide is turning. Advances in automated identity provisioning now enable enterprises to establish verifiable trust at the very edge, embedding security directly during manufacturing and onboarding rather than layering it on afterwards.

At the centre of this evolution is Device Authority’s KeyScaler® platform, which automates the creation and management of strong, unique device identities at industrial scale. Each identity can be anchored in hardware through Trusted Platform Modules or secure elements, or dynamically generated via Dynamic Device Key Generation when such components are absent.

The true strength of Zero Trust, however, lies in the ongoing validation of identity rather than its initial establishment. Device Authority’s partnership with Olympus integrates these trust anchors into identity and access management frameworks where policies continuously adapt to device health, behaviour, and operational context.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines examines factors influencing prescribing decisions

Talking Medicines explains how healthcare professional conversations, clinical considerations and treatment perceptions can provide pharmaceutical companies with deeper insight into prescribing intent beyond traditional campaign metrics.

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Search